SCHEMBL5739656

SCHEMBL5739656

CC(C(=O)NN)c1ccc(O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.51
CRHBP P24387 2/20 0.51
CRHR2 Q13324 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ESR1 P03372 3/20 0.46
ESR2 Q92731 3/20 0.46
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
MPO P05164 1/20 0.45
CYP3A4 P08684 1/20 0.45
KDM5A P29375 1/20 0.45
BLM P54132 1/20 0.45
GFER P55789 1/20 0.45
PMP22 Q01453 1/20 0.45
HIF1A Q16665 1/20 0.45
CXCR1 P25024 3/20 0.44
CXCR2 P25025 3/20 0.44
CHRM1 P11229 1/20 0.43
PDE4A P27815 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739780 0.82 ALDH1A1 (0.57) GAACXCR1CXCR2CHRM1PDE4A
SCHEMBL6266741 0.82 CTSD (0.64) CTSD
SCHEMBL23453428 0.82 MAPT (0.57) MAPTGAACRHBPCRHR2SMN1; SMN2
Hydrochloric Acid SCHEMBL1533490 0.80 CTSD (0.62) CTSDALDH1A1
Hydrochloric Acid SCHEMBL1533249 0.80 CTSD (0.62) CTSDALDH1A1
Hydrochloric Acid SCHEMBL1533250 0.80 CTSD (0.62) CTSDALDH1A1
SCHEMBL5741082 0.79 GPR88 (0.55) MAPTGAACYP3A4CXCR1CXCR2
SCHEMBL2827910 0.78 CYP3A4 (0.47) SMN1; SMN2MPOCYP3A4CTSDALDH1A1
SCHEMBL577665 0.78 CHRM1 (0.73) MAPTGAACRHBPCRHR2SMN1; SMN2
SCHEMBL30465076 0.78 CHRM1 (0.73) MAPTGAACRHBPCRHR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644362-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS Sugen, Inc. (US) 2006-04-12 EP disclosed
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors SUGEN, INC. 2006-01-12 US disclosed
WO-2005005378-A2 INDOLINONE HYDRAZIDES AS C-MET INHIBITORS SUGEN, INC. (US) 2005-01-20 WO disclosed
EP-0648612-B1 Reversible heat-sensitive recording material MITSUBISHI PAPER MILLS LTD (JP) 1998-06-10 EP disclosed
US-5498772-A SUBSTRATE WITH HEAT SENSITIVE LAYER AND OPTICAL RECORDING LAYER MITSUBISHI PAPER MILLS LIMITED (JP) 1996-03-12 US disclosed
EP-0648612-A1 Reversible heat-sensitive recording material MITSUBISHI PAPER MILLS, LTD. (JP) 1995-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009493-A1 Indolinone hydrazides as c-Met inhibitors MET, IGF1R, ROS1 MAPT 3977/4885GAA 3630/4885CRHBP 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.